Crispr Therapeutics Stock Been: A Roller-Coaster Year Unpacked
CRISPR Therapeutics stock has zigzagged all year, driven by pipeline milestones, regulatory updates, and funding need...
Total return indices show comprehensive performance by including dividends. Understanding them helps investors assess risk and compare strategies effectively.
27,899 articlesCRISPR Therapeutics stock has zigzagged all year, driven by pipeline milestones, regulatory updates, and funding need...
A landmark agreement between Apple and Broadcom signals a major shift in chip strategy and domestic manufacturing. Th...
Sam Altman is driving OpenAI toward a trillion-dollar target, while SoftBank faces a substantial loan due in 2027. Th...
Cathie Wood's Ark Invest has been quietly loading up on Nvidia this week. Here are three solid reasons why her buying...
Investors watch WWDC 2026 with high expectations as Apple readies a major AI push. This preview outlines what’s at st...
Micron stock sinking today signals short-term selling pressure in a volatile memory market. This article breaks down ...
Oracle is set to report its June quarter as AI demand tests the cloud backbone. Backlog and RPO could reveal real app...
In June’s shifting markets, automation stocks like UiPath are under the microscope. This article explains why ARR gro...
A new Fed chair angles for a disciplined inflation fight and a leaner balance sheet, even as markets seek clarity. He...
Netflix just posted a record quarterly revenue, but the forecast for the next quarter came in softer than expected. H...
Rumors of a setback around Nvidia s Vera Rubin AI rollout stirred investor nerves. In contrast, Jensen Huang has insi...
MannKind reported a double-digit revenue rise, but the stock still slid on Thursday. This article breaks down why the...